AIPAC (Active Immunotherapy PAClitaxel): A randomized, double blind, placebo controlled, multinational phase IIb trial evaluating the efficacy of eftilagimod alpha (a soluble LAG-3 fusion protein) in combination with paclitaxel in hormone receptor positive metastatic breast cancer

被引：0

作者：

Dirix, Luc ^{[1
]}

Wildiers, Hans ^{[2
,3
]}

Huizing, Manon T. ^{[4
]}

De Cuypere, Eveline ^{[5
]}

Schroder, Carolina P. ^{[6
]}

Armstrong, Anne C. ^{[7
]}

Huober, Jans ^{[8
]}

Marme, Frederik ^{[9
]}

Schneeweiss, Andreas ^{[10
]}

Khan, Sarah ^{[11
]}

Triebel, Frederic ^{[12
]}

机构：

[1] Sint Augustinus, Antwerp, Belgium

[2] Univ Hosp Leuven, Dept Gen Med Oncol, Leuven, Belgium

[3] Univ Hosp Leuven, Multidisciplinary Breast Ctr, Leuven, Belgium

[4] UZA, Breast & Gynaecol Oncol Unit, Antwerp, Belgium

[5] AZ Sint Jan Burgge Oostende AV, VZW Oncol Ctr, Brugge, Belgium

[6] Univ Med Ctr Groningen, Groningen, Netherlands

[7] Christie NHS Fdn Trust, Clin Med Oncol, Manchester, Lancs, England

[8] Univ Clin Women, Ulm, Germany

[9] Heidelberg Univ, Univ Clin Mannheim, Gynaecol Oncol, Mannheim, Germany

[10] Natl Ctr Tumor Dis, Heidelberg, Germany

[11] Notthingham Univ Hosp NHS Trust, Clin Oncol, Nottingham, England

[12] Immutep SAS, Res & Dev, Orsay, France

来源：

关键词：

D O I：

10.1158/1538-7445.SABCS19-OT1-01-05

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OT1-01-05

引用

页数：2